Loading data for ACXP — first visit, this takes a few seconds.

Acurx Pharmaceuticals Inc...

NasdaqCM: ACXP · Real-Time Price · USD
1.40
-0.07 (-4.76%)
At close: Aug 24, 2026, 8:00 PM

The price, the headline numbers and the latest news, in one place.

Acurx Pharmaceuticals Inc. (ACXP) Stock Price, Analysis & Data

-4.76%

No data available

Bid1.05
Market Cap6.02M
Revenue (ttm)n/a
Net Income (ttm)-7.51M
-2.03
-2.44
n/a
-0.8
P/B (ttm)0.80
P/S (ttm)n/a
Earnings DateNov 11, 2026
Ask1.81
Volume132,545
Avg. Volume (20D)123,479
Open1.47
Previous Close1.47
Day's Range1.40 - 1.49
52-Week Range1.31 - 8.34
Analystn/a
Price Targetn/a
Dividendsn/a
Ex-Dividend Daten/a

About ACXP

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-pos...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 25, 2021
Employees 4
Stock Exchange NasdaqCM
Ticker Symbol ACXP
Full Company Profile

Financial Performance

In 2025, Acurx Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -7.97M, a decrease of -43.51%.

Financial Statements

Earnings Surprise

Acurx Pharmaceuticals has released their quarterly earnings on Aug 13, 2026:
  • Revenue of $0 misses estimates by $0, with NaN% YoY growth.
  • EPS of -0.53 misses estimates by -0.10, with 71.96% YoY growth.
Acurx Pharmaceuticals Inc. is scheduled to release its earnings on Nov 11, 2026, before market opens.
Analysts project revenue of ... Upgrade